ITMI20021392A1 - Forme farmaceutiche per la somministrazione orale di farmaci liquidi a temperatura ambiente dotate di migliore biodisponibilita' - Google Patents

Forme farmaceutiche per la somministrazione orale di farmaci liquidi a temperatura ambiente dotate di migliore biodisponibilita'

Info

Publication number
ITMI20021392A1
ITMI20021392A1 IT2002MI001392A ITMI20021392A ITMI20021392A1 IT MI20021392 A1 ITMI20021392 A1 IT MI20021392A1 IT 2002MI001392 A IT2002MI001392 A IT 2002MI001392A IT MI20021392 A ITMI20021392 A IT MI20021392A IT MI20021392 A1 ITMI20021392 A1 IT MI20021392A1
Authority
IT
Italy
Prior art keywords
liquid drugs
ambient temperature
oral administration
pharmaceutical forms
better bioavailability
Prior art date
Application number
IT2002MI001392A
Other languages
English (en)
Inventor
Giancarlo Santus
Soldato Piero Del
Cristina Macelloni
Original Assignee
Nicox Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nicox Sa filed Critical Nicox Sa
Priority to IT2002MI001392A priority Critical patent/ITMI20021392A1/it
Publication of ITMI20021392A0 publication Critical patent/ITMI20021392A0/it
Priority to CA002491152A priority patent/CA2491152A1/en
Priority to DK03760660T priority patent/DK1526839T3/da
Priority to AU2003246564A priority patent/AU2003246564B2/en
Priority to JP2004514802A priority patent/JP2005530835A/ja
Priority to EP03760660A priority patent/EP1526839B1/en
Priority to NZ537204A priority patent/NZ537204A/en
Priority to ES03760660T priority patent/ES2285182T3/es
Priority to US10/515,621 priority patent/US20060171969A1/en
Priority to KR1020047021307A priority patent/KR20060076136A/ko
Priority to MXPA04012852A priority patent/MXPA04012852A/es
Priority to PL374388A priority patent/PL206599B1/pl
Priority to AT03760660T priority patent/ATE356612T1/de
Priority to RU2004138554/15A priority patent/RU2323003C2/ru
Priority to PT03760660T priority patent/PT1526839E/pt
Priority to SI200330822T priority patent/SI1526839T1/sl
Priority to DE60312523T priority patent/DE60312523T2/de
Priority to PCT/EP2003/006496 priority patent/WO2004000273A1/en
Priority to CNB038151812A priority patent/CN1319518C/zh
Priority to IL16560103A priority patent/IL165601A0/xx
Priority to HK06100214.4A priority patent/HK1080364B/zh
Publication of ITMI20021392A1 publication Critical patent/ITMI20021392A1/it
Priority to ZA200410109A priority patent/ZA200410109B/xx
Priority to NO20050347A priority patent/NO20050347L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/4261,3-Thiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/4709Non-condensed quinolines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • A61K9/107Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/143Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IT2002MI001392A 2002-06-25 2002-06-25 Forme farmaceutiche per la somministrazione orale di farmaci liquidi a temperatura ambiente dotate di migliore biodisponibilita' ITMI20021392A1 (it)

Priority Applications (23)

Application Number Priority Date Filing Date Title
IT2002MI001392A ITMI20021392A1 (it) 2002-06-25 2002-06-25 Forme farmaceutiche per la somministrazione orale di farmaci liquidi a temperatura ambiente dotate di migliore biodisponibilita'
HK06100214.4A HK1080364B (zh) 2002-06-25 2003-06-20 具有改进的生物利用率的液体药物口服药物剂型
MXPA04012852A MXPA04012852A (es) 2002-06-25 2003-06-20 Formas farmaceutica orales de farmacos liquidos que tienen biodisponibilidad mejorada.
AT03760660T ATE356612T1 (de) 2002-06-25 2003-06-20 Orale, pharmazeutische darreichungsformen von flüssigen medikamenten mitverbesserter bioverfügbarkeit
AU2003246564A AU2003246564B2 (en) 2002-06-25 2003-06-20 Oral pharmaceutical forms of liquid drugs having improved bioavailability
JP2004514802A JP2005530835A (ja) 2002-06-25 2003-06-20 改良された生物学的利用能を有する液体薬剤の経口医薬形態
EP03760660A EP1526839B1 (en) 2002-06-25 2003-06-20 Oral pharmaceutical forms of liquid drugs having improved bioavailability
NZ537204A NZ537204A (en) 2002-06-25 2003-06-20 Oral pharmaceutical forms of liquid drugs having improved bioavailability
ES03760660T ES2285182T3 (es) 2002-06-25 2003-06-20 Farmacos liquidos en formas orales solidas que tienen biodisponibilidad mejorada.
US10/515,621 US20060171969A1 (en) 2002-06-25 2003-06-20 Oral pharmaceutical forms of liquid drugs having improved bioavailability
KR1020047021307A KR20060076136A (ko) 2002-06-25 2003-06-20 향상된 생체이용율을 가진 액상 약제들의 경구적 조제형태들
CA002491152A CA2491152A1 (en) 2002-06-25 2003-06-20 Oral pharmaceutical forms of liquid drugs having improved bioavailability
PL374388A PL206599B1 (pl) 2002-06-25 2003-06-20 Kompozycje farmaceutyczne do podawania doustnego ciekłych leków
DK03760660T DK1526839T3 (da) 2002-06-25 2003-06-20 Orale farmaceutiske former for flydende lægemidler med forbedret biotilgængelighed
RU2004138554/15A RU2323003C2 (ru) 2002-06-25 2003-06-20 Пероральные фармацевтические формы жидких лекарственных средств, имеющих улучшенную биодоступность
PT03760660T PT1526839E (pt) 2002-06-25 2003-06-20 Formas farmacêuticas orais de fármacos líquidos com biodisponibilidade melhorada
SI200330822T SI1526839T1 (sl) 2002-06-25 2003-06-20 Oralne farmacevtske oblike tekočih zdravil z izboljšano biološko uporabnostjo
DE60312523T DE60312523T2 (de) 2002-06-25 2003-06-20 Orale, pharmazeutische Darreichungsformen von flüssigen Medikamenten mit verbesserter Bioverfügbarkeit
PCT/EP2003/006496 WO2004000273A1 (en) 2002-06-25 2003-06-20 Oral pharmaceutical forms of liquid drugs having improved bioavailability
CNB038151812A CN1319518C (zh) 2002-06-25 2003-06-20 具有改进的生物利用率的液体药物口服药物剂型
IL16560103A IL165601A0 (en) 2002-06-25 2003-06-20 Oral pharmaceutical forms of liquid drugs having improved bioavailability
ZA200410109A ZA200410109B (en) 2002-06-25 2004-12-14 Oral pharmaceutical forms of liquid drugs having improved bioavailability.
NO20050347A NO20050347L (no) 2002-06-25 2005-01-21 Flytende legemidler i oral farmasoytisk form med bedret biotilgjengelighet

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT2002MI001392A ITMI20021392A1 (it) 2002-06-25 2002-06-25 Forme farmaceutiche per la somministrazione orale di farmaci liquidi a temperatura ambiente dotate di migliore biodisponibilita'

Publications (2)

Publication Number Publication Date
ITMI20021392A0 ITMI20021392A0 (it) 2002-06-25
ITMI20021392A1 true ITMI20021392A1 (it) 2003-12-29

Family

ID=11450079

Family Applications (1)

Application Number Title Priority Date Filing Date
IT2002MI001392A ITMI20021392A1 (it) 2002-06-25 2002-06-25 Forme farmaceutiche per la somministrazione orale di farmaci liquidi a temperatura ambiente dotate di migliore biodisponibilita'

Country Status (23)

Country Link
US (1) US20060171969A1 (it)
EP (1) EP1526839B1 (it)
JP (1) JP2005530835A (it)
KR (1) KR20060076136A (it)
CN (1) CN1319518C (it)
AT (1) ATE356612T1 (it)
AU (1) AU2003246564B2 (it)
CA (1) CA2491152A1 (it)
DE (1) DE60312523T2 (it)
DK (1) DK1526839T3 (it)
ES (1) ES2285182T3 (it)
HK (1) HK1080364B (it)
IL (1) IL165601A0 (it)
IT (1) ITMI20021392A1 (it)
MX (1) MXPA04012852A (it)
NO (1) NO20050347L (it)
NZ (1) NZ537204A (it)
PL (1) PL206599B1 (it)
PT (1) PT1526839E (it)
RU (1) RU2323003C2 (it)
SI (1) SI1526839T1 (it)
WO (1) WO2004000273A1 (it)
ZA (1) ZA200410109B (it)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1303671B1 (it) * 1998-07-28 2001-02-23 Nicox Sa Sali dell'acido nitrico con farmaci attivi nel trattamento dipatologie del sistema respiratorio
US20030148818A1 (en) * 2002-01-18 2003-08-07 Myrhum Mark C. Golf club woods with wood club head having a selectable center of gravity and a selectable shaft
SE0200895D0 (sv) * 2002-03-22 2002-03-22 Astrazeneca Ab New pharmaceutical composition
CA2487414A1 (en) 2002-06-11 2003-12-18 Nitromed, Inc. Nitrosated and/or nitrosylated cyclooxygenase-2 selective inhibitors, compositions and methods of use
WO2004004648A2 (en) 2002-07-03 2004-01-15 Nitromed, Inc. Nitrosated nonsteroidal antiinflammatory compounds, compositions and methods of use
NO346973B1 (en) 2002-12-20 2023-03-20 Niconovum Ab A physically and chemically stable nicotine-containing particulate material
FR2873923B1 (fr) * 2004-08-05 2007-01-12 Gattefosse Holding Sa Particule solide anhydre contenant une composition lipidique liquide et composition pharmaceutique contenant lesdites particules
WO2006085217A2 (en) * 2005-02-08 2006-08-17 Pfizer Products Inc. Solid adsorbates of hydrophobic drugs
US20090004347A1 (en) * 2005-03-04 2009-01-01 Bengt Herslof Foodstuff Particulate Lipid Composition
EP1933876A1 (en) * 2005-09-16 2008-06-25 DSM IP Assets B.V. Particulate lipid pharmaceutical composition
WO2007060112A1 (en) 2005-11-23 2007-05-31 Nicox S.A. Salicylic acid derivatives
PT1978947E (pt) * 2006-02-03 2014-11-03 Nicox Science Ireland Derivados nitro-óxido para utilização no tratamento de distrofias musculares
EP1998748B1 (en) 2006-03-16 2015-01-14 NicoNovum AB Improved snuff composition
DE202008018063U1 (de) * 2007-04-25 2011-10-11 Teva Pharmaceutical Industries Ltd. Pharmazeutischer Hilfsstoffkomplex
WO2009149053A2 (en) * 2008-06-02 2009-12-10 Dr. Reddy's Laboratories Ltd. Naproxcinod process and solid dispersion
US20130078307A1 (en) 2011-09-22 2013-03-28 Niconovum Usa, Inc. Nicotine-containing pharmaceutical composition
US9474303B2 (en) 2011-09-22 2016-10-25 R.J. Reynolds Tobacco Company Translucent smokeless tobacco product
US9629392B2 (en) 2011-09-22 2017-04-25 R.J. Reynolds Tobacco Company Translucent smokeless tobacco product
US9084439B2 (en) 2011-09-22 2015-07-21 R.J. Reynolds Tobacco Company Translucent smokeless tobacco product
US9763928B2 (en) 2012-02-10 2017-09-19 Niconovum Usa, Inc. Multi-layer nicotine-containing pharmaceutical composition
US9044035B2 (en) 2012-04-17 2015-06-02 R.J. Reynolds Tobacco Company Remelted ingestible products
ES2821528T3 (es) 2012-11-14 2021-04-26 Grace W R & Co Composiciones que contienen un material biológicamente activo y un óxido inorgánico no ordenado
CN102964250A (zh) * 2012-11-19 2013-03-13 吉林大学 氟比洛芬丁香酚酯药用化合物及其制剂和制备方法
CA2904045C (en) 2013-03-13 2022-03-29 Tris Pharma, Inc. Benzonatate modified release solid tablets and capsules
US9180104B2 (en) 2013-03-13 2015-11-10 Tris Pharma, Inc. Benzonatate modified release solid tablets and capsules
US11826462B2 (en) 2019-12-09 2023-11-28 Nicoventures Trading Limited Oral product with sustained flavor release
US12310959B2 (en) 2019-12-09 2025-05-27 Nicoventures Trading Limited Oral compositions with reduced water content
US11793230B2 (en) 2019-12-09 2023-10-24 Nicoventures Trading Limited Oral products with improved binding of active ingredients
EP4072516A1 (en) 2019-12-09 2022-10-19 Nicoventures Trading Limited Oral product comprising a cannabinoid
US11617744B2 (en) 2019-12-09 2023-04-04 Nico Ventures Trading Limited Moist oral compositions
US11969502B2 (en) 2019-12-09 2024-04-30 Nicoventures Trading Limited Oral products
US11872231B2 (en) 2019-12-09 2024-01-16 Nicoventures Trading Limited Moist oral product comprising an active ingredient
US12433321B2 (en) 2019-12-09 2025-10-07 Nicoventures Trading Limited Oral composition with beet material
MX2022007085A (es) * 2019-12-09 2022-08-19 Nicoventures Trading Ltd Nanoemulsion para uso oral.
EP4358748A1 (en) 2021-06-25 2024-05-01 Nicoventures Trading Limited Oral products and method of manufacture
EP4426694A1 (en) 2021-11-05 2024-09-11 Cinclus Pharma Holding AB (publ) Polymorphs of the hydrochloride salt of linaprazan glurate

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5266615A (en) * 1975-11-29 1977-06-02 Sawai Seiyaku Kk Manufacturing of solidified oily liquid substance
JPS56169622A (en) * 1980-06-03 1981-12-26 Kissei Pharmaceut Co Ltd Method of making solid preparation from oily substance
JPS58213073A (ja) * 1982-06-07 1983-12-10 Masatoshi Yamada 油状物質の固形化法
US6054136A (en) * 1993-09-30 2000-04-25 Gattefosse S.A. Orally administrable composition capable of providing enhanced bioavailability when ingested
US5968542A (en) * 1995-06-07 1999-10-19 Southern Biosystems, Inc. High viscosity liquid controlled delivery system as a device
NZ525580A (en) * 1997-06-27 2004-08-27 Vivorx Pharmaceuticals Inc Vehicles for intravenous administration of paclitaxel having reduced toxicity
JP2000016934A (ja) * 1998-06-30 2000-01-18 Eisai Co Ltd テプレノンを含有した錠剤
ES2341510T3 (es) * 1998-08-13 2010-06-21 Cima Labs Inc. Microemulsiones como formas farmaceuticas solidas para la administracion oral.
ATE306250T1 (de) * 1998-12-23 2005-10-15 Alza Corp Dosierungsformen, die poröse partikel enthalten
US6294192B1 (en) * 1999-02-26 2001-09-25 Lipocine, Inc. Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents
IT1311924B1 (it) * 1999-04-13 2002-03-20 Nicox Sa Composti farmaceutici.
US6793934B1 (en) * 1999-12-08 2004-09-21 Shire Laboratories, Inc. Solid oral dosage form
SE0000774D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
SE0000773D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
SE0200895D0 (sv) * 2002-03-22 2002-03-22 Astrazeneca Ab New pharmaceutical composition

Also Published As

Publication number Publication date
PT1526839E (pt) 2007-06-06
MXPA04012852A (es) 2005-06-08
HK1080364A1 (en) 2006-04-28
NZ537204A (en) 2006-07-28
SI1526839T1 (sl) 2007-08-31
EP1526839A1 (en) 2005-05-04
ATE356612T1 (de) 2007-04-15
WO2004000273A1 (en) 2003-12-31
IL165601A0 (en) 2006-01-15
RU2323003C2 (ru) 2008-04-27
CN1319518C (zh) 2007-06-06
AU2003246564B2 (en) 2008-06-12
NO20050347L (no) 2005-01-21
PL206599B1 (pl) 2010-08-31
HK1080364B (zh) 2008-02-01
US20060171969A1 (en) 2006-08-03
KR20060076136A (ko) 2006-07-04
RU2004138554A (ru) 2005-08-27
CN1665486A (zh) 2005-09-07
PL374388A1 (en) 2005-10-17
ZA200410109B (en) 2005-09-02
ITMI20021392A0 (it) 2002-06-25
ES2285182T3 (es) 2007-11-16
DE60312523T2 (de) 2008-01-10
DK1526839T3 (da) 2007-05-21
JP2005530835A (ja) 2005-10-13
DE60312523D1 (de) 2007-04-26
CA2491152A1 (en) 2003-12-31
AU2003246564A1 (en) 2004-01-06
EP1526839B1 (en) 2007-03-14

Similar Documents

Publication Publication Date Title
ITMI20021392A1 (it) Forme farmaceutiche per la somministrazione orale di farmaci liquidi a temperatura ambiente dotate di migliore biodisponibilita'
NO2025027I1 (no) Pharmaceutical mixture or association that includes as active ingredients: (1) ceftazidime or a salt thereof, and (2) avibactam or a pharmaceutically acceptable salt thereof - forlenget.
TR200200561T2 (tr) Mesalazin içeren ve vücut içinde kontrollü bir şekilde salgılanabilen ağızdan alınan farmasötik bileşimler
ATE293995T1 (de) Pharmazeutische zusammensetzungen, die wirkstoffabsorptionsfördernde verbindungen enthalten
TNSN04023A1 (fr) Formulation de suspension orale stabilisee
TR200002812T2 (tr) Efervesan formülasyonları.
EP1708686A4 (en) GENERAL LINEAR SHELL FORM OF FENTANYL FOR ORAL USE AND METHOD OF ADMINISTRATION
FR2825023B1 (fr) Forme pharmaceutique orale antidiabetique "une prise par jour"comprenant une biguanide et au moins un autre principe actif
DE60023465D1 (de) Pharmazeutische formulierungen mit verbesserter löslichkeit in wasser
EA200401019A1 (ru) Дозированная лекарственная форма для перорального применения, содержащая ингибитор pde 4 в качестве действующего вещества и поливинилпирролидон в качестве вспомогательного вещества
EA200400432A1 (ru) Производные мочевины
DE69808463D1 (de) Selbstemulgierende formulierung enthaltend saure lipophile verbindungen
DE60134245D1 (de) (5-(2-hydroxy-4-chlorbenzoyl)valeriansäure und deren salze, und zusammensetzungen zur zuführung von wirkstoffen, die diese verbindungen enthalten
ITMI20021726A1 (it) Macrolidi ad attivita' antiinfiammatoria.
IS8430A (is) Lyf sem inniheldur (2R)-2-própýloktansýru sem virka efnisþáttinn
ITMI20022292A1 (it) 9a-azalidi ad attivita' antiinfiammatoria.
DK1104289T3 (da) Hidtil ukendte orale formuleringer for 5-HT4-agonister eller -antagonister
DK1401405T3 (da) Orale, farmaceutiske sammensætninger med forbedret biotilgængelighed
AR024959A1 (es) Una composicion farmaceutica liquida basada en paracetamol
BR9807330A (pt) Agentes inibidores do progresso de pterìgio e recorrência pós-operatória do mesmo
BR0302523A (pt) Composição farmacêutica estável para administração de inibidores da hiv protease e processo de obtenção de composição farmacêutica concentrada para a administração de inibidores da hiv protease
UY27920A1 (es) Combinaciones de epinastina, pseudoefedrina y metilefedrina como nuevas formulaciones farmaceuticas
FR2839645B1 (fr) Systeme multilamellaire pour l'administration de substances actives (en particulier des medicaments) par ingestion par la voie orale
BR0202252A (pt) Composição farmacêutica solúvel estável para administração de inibidores da hiv protease e processo de obtenção de composições farmacêuticas concentradas para a administração de inibidores da hiv protease
DK1275383T3 (da) "Modified release" farmaceutisk komposition, der indeholder Bupropion HCI som aktivt stof